Acquired Company

Applied Therapeutics, Inc. completed its merger with Cycle Group Holdings Limited on February 3, 2026, becoming an indirect wholly owned subsidiary of Cycle Group Holdings Limited.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to combat cardiovascular disease, galactosemia, and diabetes complications. The company is headquartered in New York, New York. Show more

545 FIFTH AVENUE, NEW YORK, NY, UNITED STATES, 10017, New York, NY, 10017, USA

https://www.appliedtherapeutics.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

14.86M

52 Wk Range

$0.09 - $1.50

Previous Close

$0.10

Open

$0.10

Volume

N/A

Day Range

$0.10 - $0.10

Enterprise Value

5.418M

Cash

11.95M

Avg Qtr Burn

-18.4M

Insider Ownership

5.49%

Institutional Own.

68.78%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Govorestat (AT-007) Details Sorbitol dehydrogenase deficiency	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Govorestat (AT-007) Details Classic Galactosemia	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Caficrestat (AT-001) Details Hemophilia, Genetic disorder, Diabetic cardiomyopathy	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Govorestat (AT-007) Details Phosphomannomutase 2 deficiency , Congenital disorder of glycosylation	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AT-003 Details Diabetic retinopathy	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AT-104 Details Leukemia, B-cell acute lymphoblastic leukemia, T-cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.